#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

The efficiency of monoclonal antibody anti-CD20 – rituximab –in the treatment of folicular lymphoma


Authors: A. Obořilová;  J. Mayer
Authors‘ workplace: Interní hematoonkologická klinika FN, Brno Bohunice
Published in: Transfuze Hematol. dnes,, 2003, No. 4, p. 170-177.
Category:

Overview

Rituximab is a chimeric monoclonal antibody anti-CD20. CD20 receptor is expressed on cells of manyB-lymphoproliferative diseases and is constantly presented on cells of follicular lymphoma. Theeffective mechanism is antibody- (ADCC) and complement-dependent cytotoxicity (CDC). There is alsoevidence of direct induction of apoptosis and inhibition of proliferation. The usual dosage of rituximabis 4x375mg/m2 in slow infusion, applied in weekly intervals. A synergism of rituximab with manycytostatics was demonstrated in vitro and also confirmed in clinical studies. Rituximab toxicity is verylow and manifests usually with a moderate allergic reaction in the course of administration of the firstinfusion. In monotherapy, rituximab leads in relapsing and resistent patients with follicular lymphomato 46-48 % of overall response (OR) and 2-6 % complete remission (CR), whereas in primary treatment,up to 70 % OR and 20 % CR have been reported. Immunochemotherapy (rituximab combinationwith chemotherapy) is even more efficient. The CHOP/rituximab regime reached 95-100 % OR and54-58 % CR, corresponding results have been described even after combinations of fludarabin regimewith rituximab. Rituximab was also administered in combination with different cytokines. The efficiencyof rituximab with IFNα was between 45-71 % OR, combination of rituximab with IL-2, IL-12 andG-CSF reached around 67-69 % OR. Rituximab is used as an efficient method of purging in vivo beforecollection of peripheral stem cells and in maintenance therapy after autologous transplantation ofperipheral stem cells.

Key words:
rituximab, mabthera, monoclonal antibodies, follicular lymphoma

Full text is not available online.
If interested in a scan of this journal, contact NTO ČLS JEP.

Labels
Haematology Internal medicine Clinical oncology
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#